JP2005532064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532064A5 JP2005532064A5 JP2004519849A JP2004519849A JP2005532064A5 JP 2005532064 A5 JP2005532064 A5 JP 2005532064A5 JP 2004519849 A JP2004519849 A JP 2004519849A JP 2004519849 A JP2004519849 A JP 2004519849A JP 2005532064 A5 JP2005532064 A5 JP 2005532064A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- modified
- polyprotein
- asp
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 189
- 102000004196 processed proteins & peptides Human genes 0.000 claims 188
- 229920001184 polypeptide Polymers 0.000 claims 186
- 108091005804 Peptidases Proteins 0.000 claims 22
- 108010076039 Polyproteins Proteins 0.000 claims 22
- 239000004365 Protease Substances 0.000 claims 22
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 22
- 238000006467 substitution reaction Methods 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 20
- 108020001507 fusion proteins Proteins 0.000 claims 20
- 102000037865 fusion proteins Human genes 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 6
- 230000024932 T cell mediated immunity Effects 0.000 claims 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39369402P | 2002-07-02 | 2002-07-02 | |
| US39451002P | 2002-07-08 | 2002-07-08 | |
| PCT/US2003/020996 WO2004005473A2 (en) | 2002-07-02 | 2003-07-02 | Hcv fusion proteins with modified ns3 domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006174595A Division JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532064A JP2005532064A (ja) | 2005-10-27 |
| JP2005532064A5 true JP2005532064A5 (2) | 2006-08-10 |
Family
ID=30118384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519849A Pending JP2005532064A (ja) | 2002-07-02 | 2003-07-02 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
| JP2006174595A Pending JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006174595A Pending JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1539809A4 (2) |
| JP (2) | JP2005532064A (2) |
| CN (1) | CN1678630A (2) |
| AU (1) | AU2003248818A1 (2) |
| CA (1) | CA2491508A1 (2) |
| PL (1) | PL374349A1 (2) |
| RU (1) | RU2005102484A (2) |
| WO (1) | WO2004005473A2 (2) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491808B2 (en) * | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| EP1576125A4 (en) * | 2002-10-25 | 2008-09-03 | Novartis Vaccines & Diagnostic | ACTIVATION OF SPECIFIC HCV LYMPHOCYTES |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CA2566725A1 (en) * | 2004-05-17 | 2005-12-01 | Chiron Corporation | Truncated hepatitis c virus ns5 domain and fusion proteins comprising same |
| EP1802778B1 (en) | 2004-08-27 | 2011-10-05 | Novartis Vaccines and Diagnostics, Inc. | Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof |
| AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP2460533A3 (en) * | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CA2618429A1 (en) * | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
| CA2623329A1 (en) * | 2005-10-13 | 2007-04-19 | Virexx Medical Corp. | Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response |
| GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| US8216590B2 (en) * | 2006-08-25 | 2012-07-10 | Novartis Ag | HCV fusion polypeptides |
| WO2010033841A1 (en) | 2008-09-19 | 2010-03-25 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis c virus infection |
| WO2012038950A1 (en) | 2010-09-20 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| CA2980718C (en) * | 2015-03-27 | 2021-06-01 | Ortho-Clinical Diagnostics, Inc. | Hcv ns4a/modified ns3 polypeptides and uses thereof |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| CN111153963B (zh) * | 2020-01-19 | 2021-08-10 | 华南理工大学 | 抗炎五肽及其提取分离方法和在改善记忆中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE236981T1 (de) * | 1993-11-04 | 2003-04-15 | Innogenetics Nv | Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis |
| WO2001038360A2 (en) * | 1999-11-24 | 2001-05-31 | Chiron Corporation | Novel hcv non-structural polypeptide |
| WO2001090812A1 (en) * | 2000-05-23 | 2001-11-29 | Massachusetts Institute Of Technology | Ultraviolet fluoride nonlinear devices |
-
2003
- 2003-07-02 AU AU2003248818A patent/AU2003248818A1/en not_active Abandoned
- 2003-07-02 CA CA002491508A patent/CA2491508A1/en not_active Abandoned
- 2003-07-02 JP JP2004519849A patent/JP2005532064A/ja active Pending
- 2003-07-02 CN CNA038207192A patent/CN1678630A/zh active Pending
- 2003-07-02 RU RU2005102484/13A patent/RU2005102484A/ru not_active Application Discontinuation
- 2003-07-02 PL PL03374349A patent/PL374349A1/xx not_active Application Discontinuation
- 2003-07-02 EP EP03763172A patent/EP1539809A4/en not_active Withdrawn
- 2003-07-02 WO PCT/US2003/020996 patent/WO2004005473A2/en not_active Ceased
-
2006
- 2006-06-23 JP JP2006174595A patent/JP2006265267A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532064A5 (2) | ||
| Leary et al. | Sequence and genomic organization of GBV‐C: A novel member of the Flaviviridae associated with human non‐A‐E hepatitis | |
| Muerhoff et al. | Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis | |
| JP2008516610A5 (2) | ||
| Ryan et al. | Virus-encoded proteinases of the Flaviviridae. | |
| RU2005102484A (ru) | Слитые белки hcv c модифицированными доменами ns3 | |
| Kato et al. | Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. | |
| Failla et al. | Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins | |
| CA2390082A1 (en) | Novel hcv non-structural polypeptide | |
| JP2007513634A5 (2) | ||
| JP2006518331A5 (2) | ||
| JP2016501015A5 (ja) | デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用 | |
| ATE499442T1 (de) | Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz | |
| CA2650591C (en) | Methods for the treatment of flavivirus infection, molecules and uses thereof | |
| CA2389206A1 (en) | Activation of hcv-specific t cells | |
| JP2006187292A5 (2) | ||
| JP2006501825A5 (2) | ||
| WO2004111082A3 (fr) | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique | |
| RU2005113692A (ru) | Вакцина против hcv | |
| WO2004048402B1 (en) | A hepatitis c virus codon optimized non-structural ns3/4a fusion gene | |
| JP2008545393A5 (2) | ||
| D’Souza et al. | Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro | |
| RU2006144714A (ru) | Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки | |
| CN107849091A (zh) | 能够在人脂肪衍生的干细胞和肝细胞中抑制丙肝病毒复制的肽及其衍生物 | |
| CN101851274B (zh) | 抑制丙型肝炎病毒侵入的多肽 |